{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:19:46Z","timestamp":1784675986905,"version":"3.55.0"},"reference-count":26,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG, Basel, Switzerland","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate individual and group long-term efficacy and safety of erenumab in individuals with episodic migraine (EM) for whom 2\u20134 prior preventatives had failed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Participants completing the 12-week double-blind treatment phase (DBTP) of the LIBERTY study could continue into an open-label extension phase (OLEP) receiving erenumab 140\u2009mg monthly for up to 3 years. Main outcomes assessed at week 112 were: \u226550%, \u226575% and 100% reduction in monthly migraine days (MMD) as group responder rate and individual responder rates, MMD change from baseline, safety and tolerability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall 240\/246 (97.6%) entered the OLEP (118 continuing erenumab, 122 switching from placebo). In total 181\/240 (75.4%) reached 112 weeks, 24.6% discontinued, mainly due to lack of efficacy (44.0%), participant decision (37.0%) and adverse events (AEs; 12.0%). The \u226550% responder rate was 57.2% (99\/173) at 112 weeks. Of \u226550% responders at the end of the DBTP, 36\/52 (69.2%) remained responders at \u226550%\u2009and 22\/52 (42.3%) at &gt;80% of visits. Of the non-responders at the end of the DBTP, 60\/185 (32.4%) converted to \u226550% responders in at least half the visits and 24\/185 (13.0%) converted to \u226550% responders in &gt;80% of visits. Change from baseline at 112 weeks in mean (SD) MMD was \u22124.2 (5.0) days. Common AEs (\u226510%) were nasopharyngitis, influenza and back pain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Efficacy was sustained over 112 weeks in individuals with difficult-to-treat EM for whom 2\u20134 prior migraine preventives had failed. Erenumab treatment was safe and well tolerated, in-line with previous studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03096834\">NCT03096834<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2021-327480","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T18:20:41Z","timestamp":1638210041000},"page":"254-262","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Two-year efficacy and safety of erenumab in participants with episodic migraine and 2\u20134 prior preventive treatment failures: results from the LIBERTY study"],"prefix":"10.1136","volume":"93","clinical-trial-number":[{"clinical-trial-number":"nct03096834","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03096834","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Michel Dominique","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3260-5904","authenticated-orcid":false,"given":"Peter J","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Paiva da Silva Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7267-8505","authenticated-orcid":false,"given":"Subhayan","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihua","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Tenenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaloo","family":"Pandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Lanteri-Minet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7722-2005","authenticated-orcid":false,"given":"Tracy","family":"Stites","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"2022021507552034000_93.3.254.1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/head.12774","article-title":"Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the chronic migraine epidemiology and outcomes (CaMEO) study","volume":"56","author":"Dodick","year":"2016","journal-title":"Headache"},{"key":"2022021507552034000_93.3.254.2","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-018-0839-1","article-title":"Poor medical care for people with migraine in Europe - evidence from the Eurolight study","volume":"19","author":"Katsarava","year":"2018","journal-title":"J Headache Pain"},{"key":"2022021507552034000_93.3.254.3","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/head.13642","article-title":"Discontinuation of acute prescription medication for migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) study","volume":"59","author":"Lipton","year":"2019","journal-title":"Headache"},{"key":"2022021507552034000_93.3.254.4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","article-title":"Systematic review of migraine prophylaxis adherence and persistence","volume":"20","author":"Hepp","year":"2014","journal-title":"J Manag Care Pharm"},{"key":"2022021507552034000_93.3.254.5","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.227793"},{"key":"2022021507552034000_93.3.254.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"2022021507552034000_93.3.254.7","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1212\/WNL.0000000000010019","article-title":"One-Year sustained efficacy of erenumab in episodic migraine: results of the strive study","volume":"95","author":"Goadsby","year":"2020","journal-title":"Neurology"},{"key":"2022021507552034000_93.3.254.8","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"2022021507552034000_93.3.254.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"2022021507552034000_93.3.254.10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0333102419894559","article-title":"The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving \u226550%, \u226575%, and 100% response","volume":"40","author":"Brandes","year":"2020","journal-title":"Cephalalgia"},{"key":"2022021507552034000_93.3.254.11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0333102420912726","article-title":"Long-Term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study","volume":"40","author":"Tepper","year":"2020","journal-title":"Cephalalgia"},{"key":"2022021507552034000_93.3.254.12","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/ene.14715","article-title":"Long-Term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial","volume":"28","author":"Ashina","year":"2021","journal-title":"Eur J Neurol"},{"key":"2022021507552034000_93.3.254.13","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1177\/0333102418788347","article-title":"Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"38","author":"Ashina","year":"2018","journal-title":"Cephalalgia"},{"key":"2022021507552034000_93.3.254.14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/0333102419835459","article-title":"Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"39","author":"Goadsby","year":"2019","journal-title":"Cephalalgia"},{"key":"2022021507552034000_93.3.254.15","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00417","article-title":"Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and OnabotulinumtoxinA: a Dual-Center retrospective observational study","volume":"11","author":"Raffaelli","year":"2020","journal-title":"Front Neurol"},{"key":"2022021507552034000_93.3.254.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32534-0"},{"key":"2022021507552034000_93.3.254.17","doi-asserted-by":"crossref","first-page":"e2724","DOI":"10.1212\/WNL.0000000000012029","article-title":"Long-Term efficacy and safety of Erenumab: results from 64 weeks of the liberty study","volume":"96","author":"Goadsby","year":"2021","journal-title":"Neurology"},{"key":"2022021507552034000_93.3.254.18","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-324396"},{"key":"2022021507552034000_93.3.254.19","first-page":"1","article-title":"Sustained efficacy and safety of erenumab in patients with episodic migraine who failed 2-4 prior preventive treatments: 2-year interim results of the liberty open-label extension study. 62nd annual scientific meeting American headache Society\u00ae","volume":"60","author":"Reuter","year":"2020","journal-title":"Headache: The Journal of Head and Face Pain"},{"key":"2022021507552034000_93.3.254.20","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"2022021507552034000_93.3.254.21","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA\u00ae) . Introductory Guide MedDRA Version 22.1. A registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). [Internet], 2019."},{"key":"2022021507552034000_93.3.254.22","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) . Version 4.03 ed [Internet]. United States Department of Health and Human Services, 2010."},{"key":"2022021507552034000_93.3.254.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-018-1193-2","article-title":"A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine","volume":"18","author":"Camporeale","year":"2018","journal-title":"BMC Neurol"},{"key":"2022021507552034000_93.3.254.24","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled regain study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"2022021507552034000_93.3.254.25","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30279-9"},{"key":"2022021507552034000_93.3.254.26","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (focus): a randomised, double-blind, placebo-controlled, phase 3B trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2021-327480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T17:17:24Z","timestamp":1644945444000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2021-327480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2,15]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/jnnp-2021-327480"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2021-327480","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]}}}